Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th ed. US Department of Health and Human Services, Washington, DC 1994; 714–718
   Google Scholar
• Hammarbäck S, Ekholm U B, Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 1991; 125: 132–137
   PubMedGoogle Scholar
• Hammarbäck S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet. Gynecol. Scand 1988; 67: 159–166
   PubMed Web of Science ®Google Scholar
• Mortola J F, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 72: 252A–252F
   PubMed Web of Science ®Google Scholar
• Studd J, Leather A T. The need for add-back with gonadotrophin-releasing hormone agonist therapy. Br J Obstet Gynaecol 1996; 103(Suppl 14)1–4
   PubMedGoogle Scholar
• Di Carlo C, Palomba S, Tommaselli G A, Guida M, Di Spiezio Sardo A, Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75: 380–384
   PubMed Web of Science ®Google Scholar
• Rubinow D R, Hoban M C, Grover G N, Galloway D S, Roy-Byrne P, Andersen R, Merriam G R. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158: 5–11
   PubMed Web of Science ®Google Scholar
• Bäckström T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983; 6: 503–507
   Google Scholar
• Girdler S S, Pedersen C A, Stern R A, Light K C. Menstrual cycle and premenstrual syndrome: modifiers of cardiovascular reactivity in women. Health Psychol 1993; 12: 180–192
   PubMed Web of Science ®Google Scholar
• Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997; 22: 25–38
   PubMed Web of Science ®Google Scholar
• Sundström I, Nyberg S, Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997; 17: 370–381
   PubMed Web of Science ®Google Scholar
• Sundström I, Andersson A, Nyberg S, Ashbrook D, Purdy R H, Bäckström T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67: 126–138
   PubMed Web of Science ®Google Scholar
• Nyberg S, Wahlström G, Bäckström T, Sundström-Poromaa I. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology 2004; 29: 767–777
   PubMed Web of Science ®Google Scholar
• Schmidt P, Purdy R, Moore P, Jr, Paul S, Rubinow D. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256–1260
   PubMed Web of Science ®Google Scholar
• Wang M, Seippel L, Purdy R H, Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metab 1996; 81: 1076–1082
   PubMed Web of Science ®Google Scholar
• Sundström I, Bäckström T. Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol Psychiatry 1998; 44: 755–764
   PubMed Web of Science ®Google Scholar
• Rapkin A J, Morgan M, Goldman L, Brann D W, Simone D, Mahesh V B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709–714
   PubMed Web of Science ®Google Scholar
• Bicikova M, Dibbelt L, Hill M, Hampl R, Starka L. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998; 30: 227–230
   PubMed Web of Science ®Google Scholar
• Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani A D, Luisi M, Petraglia F, Genazzani A R. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000; 142: 269–273
   PubMed Web of Science ®Google Scholar
• Lombardi I, Luisi S, Quirici B, Monteleone P, Bernardi F, Liut M, Casarosa E, Palumbo M, Petraglia F, Genazzani A R. Adrenal response to adrenocorticotropic hormone stimulation in patients with premenstrual syndrome. Gynecol Endocrinol 2004; 18: 79–87
   PubMed Web of Science ®Google Scholar
• Nyberg S, Andersson A, Zingmark E, Wahlström G, Bäckström T, Sundström-Poromaa I. The effect of a low dose of alcohol on allopregnanolone serum concentrations across the menstrual cycle in women with severe premenstrual syndrome and controls. Psychoneuroendocrinology 2005; 30: 892–901
   PubMed Web of Science ®Google Scholar
• Girdler S S, Straneva P A, Light K C, Pedersen C A, Morrow A L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001; 49: 788–797
   PubMed Web of Science ®Google Scholar
• Freeman E W, Frye C A, Rickels K, Martin P A, Smith S S. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 2002; 22: 516–520
   PubMed Web of Science ®Google Scholar
• Andréen L, Sundström-Poromaa I, Bixo M, Andersson A, Nyberg S, Bäckström T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 2005; 30: 212–224
   PubMed Web of Science ®Google Scholar
• Sundström I, Nyberg S, Bixo M, Hammarbäck S, Bäckström T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78: 891–899
   PubMed Web of Science ®Google Scholar
• Ottander U, Poromaa I S, Bjurulf E, Skytt A, Bäckström T, Olofsson J I. Allopregnanolone and pregnanolone are produced by the human corpus luteum. Mol Cell Endocrinol 2005; 239: 37–44
   PubMed Web of Science ®Google Scholar
• Hammarbäck S, Bäckström T, MacGibbon Tayler B. Diagnosis of premenstrual tension syndrome: description and evaluation of a procedure for diagnosis and differential diagnosis. J Psychosom Obstet Gynecol 1989; 10: 25–42
   Web of Science ®Google Scholar
• Purdy R H, Moore P H, Jr, Rao P N, Hagino N, Yamaguchi T, Schmidt P, Rubinow D R, Morrow A L, Paul S M. Radioimmunoassay of 3α-hydroxy-5α-pregnan-20-one in rat and human plasma. Steroids 1990; 55: 290–296
   PubMed Web of Science ®Google Scholar
• Timby E, Balgard M, Nyberg S, Spigset O, Andersson A, Porankiewicz-Asplund J, Purdy R H, Zhu D, Bäckström T, Poromaa I S. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl) 2005; 186: 1–11
   Web of Science ®Google Scholar
• Türkmen S, Löfgren M, Birzniece V, Bäckström T, Johansson I M. Tolerance development to Morris water maze test impairments induced by acute allopregnanolone. Neuroscience 2006; 139: 651–659
   PubMed Web of Science ®Google Scholar
• Zhu D, Birzniece V, Bäckström T, Wahlström G. Dynamic aspects of acute tolerance to allopregnanolone evaluated using anaesthesia threshold in male rats. Br J Anaesth 2004; 93: 560–567
   PubMed Web of Science ®Google Scholar
• Bäckström T, Andréen L, Birzniece V, Björn I, Johansson I M, Nordenstam-Haghjo M, Nyberg S, Sundström-Poromaa I, Wahlström G, Wang M, et al. The role of hormones and hormonal treatment in premenstrual syndrome. CNS Drugs 2003; 17: 325–342
   PubMed Web of Science ®Google Scholar
• Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T. Allopregnanolone concentration and mood – a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl) 2006; 187: 209–221
   PubMed Web of Science ®Google Scholar
• Carl P, Hogskilde S, Nielsen J W, Sorensen M B, Lindholm M, Karlen B, Bäckström T. Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent. Anaesthesia 1990; 45: 189–197
   PubMed Web of Science ®Google Scholar
• Bäckström T, Andersson A, Andréen L, Birzniece V, Bixo M, Björn I, Haage D, Isaksson M, Johansson I M, Lindblad C, et al. Pathogenesis in menstrual cycle-linked CNS disorders. Ann NY Acad Sci 2003; 1007: 42–53
   PubMed Web of Science ®Google Scholar
• Lee G P, Loring D W, Meador K J, Flanigin H F, Brooks B S. Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion. Neurology 1988; 38: 1233–1236
   PubMed Web of Science ®Google Scholar
• Cherek D R, Spiga R, Egli M. Effects of response requirement and alcohol on human aggressive responding. J Exp Anal Behav 1992; 58: 577–587
   PubMed Web of Science ®Google Scholar
• Dougherty D M, Cherek D R, Bennett R H. The effects of alcohol on the aggressive responding of women. J Stud Alcohol 1996; 57: 178–186
   PubMedGoogle Scholar
• Beauchamp M H, Ormerod B K, Jhamandas K, Boegman R J, Beninger R. J. Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol Biochem Behav 2000; 67: 29–35
   PubMed Web of Science ®Google Scholar
• Masia S L, Perrine K, Westbrook L, Alper K, Devinsky O. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology 2000; 54: 1691–1693
   PubMed Web of Science ®Google Scholar
• Ben-Porath D D, Taylor S P. The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation. Addict Behav 2002; 27: 167–177
   PubMed Web of Science ®Google Scholar
• Wenzel R R, Bartel T, Eggebrecht H, Philipp T, Erbel R. Central-nervous side effects of midazolam during transesophageal echocardiography. J Am Soc Echocardiogr 2002; 15: 1297–1300
   PubMed Web of Science ®Google Scholar
• Miczek K A, Fish E W, De Bold J F. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm Behav 2003; 44: 242–257
   PubMed Web of Science ®Google Scholar
• Björn I, Bixo M, Nöjd K S, Collberg P, Nyberg S, Sundström-Poromaa I, Bäckström T. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol 2002; 16: 1–8
   PubMed Web of Science ®Google Scholar
• Andréen L, Bixo M, Nyberg S, Sundström-Poromaa I, Bäckström T. Progesterone effects during sequential hormone replacement therapy. Eur J Endocrinol 2003; 148: 571–577
   PubMed Web of Science ®Google Scholar
• Wang M, Hammarbäck S, Lindhe B A, Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74: 803–808
   PubMed Web of Science ®Google Scholar
• Freeman E W, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999; 156: 1403–1408
   PubMed Web of Science ®Google Scholar
• Yonkers K A, Clark R H, Trevedi M H. The psychopharmacological treatment of non major mood disorders. Modern problems in pharmacopsychiatry, A J Rush. Karger, Basel 1997; 25: 146–166
   Google Scholar
• Magos A L, Brincat M, Studd J W. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. Br Med J (Clin Res Ed) 1986; 292: 1629–1633
   PubMed Web of Science ®Google Scholar
• Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995; 346: 1231
   PubMed Web of Science ®Google Scholar
• Sher L. The placebo effect on mood and behavior: the role of the endogenous opioid system. Med Hypotheses 1997; 48: 347–349
   PubMed Web of Science ®Google Scholar